Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 2, pp 576–582 | Cite as

Hepatic Angiosarcoma: A Multi-institutional, International Experience with 44 Cases

  • Gregory C. Wilson
  • Nuria Lluis
  • Michael A. Nalesnik
  • Aziza Nassar
  • Teresa Serrano
  • Emilio Ramos
  • Michael Torbenson
  • Horacio J. Asbun
  • David A. GellerEmail author
Hepatobiliary Tumors

Abstract

Background

Hepatic angiosarcoma is a rare primary liver tumor. The aim of this current study was to evaluate the presentation and treatment outcomes in a modern cohort.

Methods

This was a retrospective, multi-institutional, observational study of patients with histopathologic diagnoses of primary hepatic angiosarcoma from four institutions. Clinicopathologic characteristics, treatments, and patient outcomes were examined.

Results

Forty-four patients with hepatic angiosarcoma were identified. Patients were predominantly Caucasian and presented at a median age of 63.7 years; 81.4% of patients had bilobar disease and 37.2% had metastatic disease at the time of presentation. Only 10 patients underwent surgical resection. Median overall survival for the entire cohort was 5.8 months (interquartile range 1.9–16.4), and 1-, 3-, and 5-year actual survival was 30.0%, 8.1%, and 5.6%, respectively. There were only two 5-year survivors, both of whom presented with localized disease and underwent curative resection.

Conclusion

The prognosis for hepatic angiosarcoma remains quite poor. Surgical resection for localized disease results in the best outcomes. Unfortunately, current imaging modalities are often non- diagnostic, and most patients are unresectable at the time of presentation.

Notes

Disclosure

Gregory C. Wilson, Nuria Lluis, Michael A. Nalesnik, Aziza Nassar, Teresa Serrano, Emilio Ramos, Michael Torbenson, Horacio J. Asbun, and David A. Geller have no conflicts of interest to declare.

References

  1. 1.
    Hamilton SRA, Lauri A. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.Google Scholar
  2. 2.
    Falk H, Herbert J, Crowley S, et al. Epidemiology of hepatic angiosarcoma in the United States: 1964–1974. Environ Health Perspect. 1981;41:107–13.CrossRefGoogle Scholar
  3. 3.
    Chaudhary P, Bhadana U, Singh RA, Ahuja A. Primary hepatic angiosarcoma. Eur J Surg Oncol. 2015;41(9):1137–43.CrossRefGoogle Scholar
  4. 4.
    Groeschl RT, Miura JT, Oshima K, Gamblin TC, Turaga KK. Does histology predict outcome for malignant vascular tumors of the liver? J Surg Oncol. 2014;109(5):483–6.CrossRefGoogle Scholar
  5. 5.
    Almogy G, Lieberman S, Gips M, et al. Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol. 2004;30(4):421–7.CrossRefGoogle Scholar
  6. 6.
    Duan XF, Li Q. Primary hepatic angiosarcoma: a retrospective analysis of 6 cases. J Dig Dis. 2012;13(7):381–5.CrossRefGoogle Scholar
  7. 7.
    Zhu YP, Chen YM, Matro E, et al. Primary hepatic angiosarcoma: a report of two cases and literature review. World J Gastroenterol. 2015;21(19):6088–96.CrossRefGoogle Scholar
  8. 8.
    Matthaei H, Krieg A, Schmelzle M, et al. Long-term survival after surgery for primary hepatic sarcoma in adults. Arch Surg. 2009;144(4):339–44 (discussion 344).CrossRefGoogle Scholar
  9. 9.
    Molina E, Hernandez A. Clinical manifestations of primary hepatic angiosarcoma. Dig Dis Sci. 2003;48(4):677–82.CrossRefGoogle Scholar
  10. 10.
    Antonescu C. Malignant vascular tumors: an update. Mod Pathol. 2014;27 Suppl 1:S30–8.CrossRefGoogle Scholar
  11. 11.
    Konstantinidis IT, Nota C, Jutric Z, et al. Primary liver sarcomas in the modern era: resection or transplantation? J Surg Oncol. 2018;117(5):886–91.CrossRefGoogle Scholar
  12. 12.
    Li DB, Si XY, Wan T, Zhou YM. A pooled analysis of treatment and prognosis of hepatic angiosarcoma in adults. Hepatobiliary Pancreat Dis Int. 2018;17(3):198–203.CrossRefGoogle Scholar
  13. 13.
    Kim HR, Rha SY, Cheon SH, Roh JK, Park YN, Yoo NC. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. Ann Oncol. 2009;20(4):780–7.CrossRefGoogle Scholar
  14. 14.
    Timaran CH, Grandas OH, Bell JL. Hepatic angiosarcoma: long-term survival after complete surgical removal. Am surg. 2000;66(12):1153–7.Google Scholar
  15. 15.
    Rosales A, Que FG. Spontaneous hepatic hemorrhage: a single institution’s 16-year experience. Am Surg. 2016;82(11):1117–20.Google Scholar
  16. 16.
    Orlando G, Adam R, Mirza D, et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation—the European Liver Transplant Registry experience. Transplantation. 2013;95(6):872–7.CrossRefGoogle Scholar
  17. 17.
    Park YS, Kim JH, Kim KW, et al. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. Clin Radiol. 2009;64(8):779–85.CrossRefGoogle Scholar
  18. 18.
    Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983–91.CrossRefGoogle Scholar
  19. 19.
    Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69(18):7175–9.CrossRefGoogle Scholar
  20. 20.
    Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer. 2011;50(1):25–33.CrossRefGoogle Scholar
  21. 21.
    Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97(1):74–81.CrossRefGoogle Scholar
  22. 22.
    Zietz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153(5):1425–33.CrossRefGoogle Scholar
  23. 23.
    van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2012;379(9829):1879–86.CrossRefGoogle Scholar
  24. 24.
    Painter C, Dunphy M, Anastasio E, et al. The Angiosarcoma Project: generating the genomic landscape of a rare cancer through a direct-to-patient initiative. J Clin Oncol. 2017;35(15 Suppl):1519.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Gregory C. Wilson
    • 1
  • Nuria Lluis
    • 2
    • 4
  • Michael A. Nalesnik
    • 3
  • Aziza Nassar
    • 2
  • Teresa Serrano
    • 4
  • Emilio Ramos
    • 4
  • Michael Torbenson
    • 5
  • Horacio J. Asbun
    • 2
    • 6
  • David A. Geller
    • 1
    Email author
  1. 1.Department of Surgery, Division of Hepatobiliary and Pancreatic SurgeryUniversity of Pittsburgh Medical CenterPittsburghUSA
  2. 2.Departments of Surgery and PathologyMayo Clinic FloridaJacksonvilleUSA
  3. 3.Department of PathologyUniversity of Pittsburgh Medical CenterPittsburghUSA
  4. 4.Department of SurgeryHospital Universitario de BellvitgeBarcelonaSpain
  5. 5.Department of PathologyMayo Clinic RochesterRochesterUSA
  6. 6.Department of Surgical OncologyMiami Cancer InstituteMiamiUSA

Personalised recommendations